Amylyx Focuses on Phase 3 Avexitide Trial in 2026
"2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline," said Joshua Cohen and Justin Klee, co-CEOs of Amylyx. "In 2026, our primary focus is on our Phase 3 LUCIDITY trial of avexitide in PBH. With recruitment of LUCIDITY complete, we are on track to complete enrollment this month and continue to expect topline data in Q3 2026. We designed LUCIDITY with the goal of replicating and building on the robust body of evidence demonstrating statistically significant reductions in hypoglycemic events observed in five prior clinical trials of avexitide in PBH. We continue to be encouraged by the high participant interest and broad engagement seen across the LUCIDITY trial sites."
